Bet_Noire/iStock via Getty Images
MorphoSys(NASDAQ:MOR) said a Phase 3 study for its drug pelabresib met its primary endpoint in treating myelofibrosis, a rare blood cancer.
German biotech company tested pelabresib in combination with JAK inhibitor ruxolitinib versus ruxolitinib plus placebo in patients who had never received JAK inhibitors. He The results showed that 66% of patients achieved at least a 35% reduction in spleen volume at week 24, compared to 35% receiving ruxolinitib and placebo.
The biotech added that key secondary endpoints assessing symptom improvement also showed a “strong positive trend” favoring the pelabresib combination.
The researchers intend to present details of the study Dec. 10 at the American Society of Hematology annual meeting in San Diego. The company expects to apply for regulatory approval of pelabresib in combination with ruxolitinib for myelofibrosis in the US and EU in mid-2024.
